Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.

Activating mutations of the B-RAF gene are observed in >60% of human melanomas. Approximately 90% of these mutations occur in the activation segment of the kinase domain as a single-base substitution that converts a valine to glutamic acid at codon 599 (V599E) in exon 15. This mutation causes activation of the kinase as well as downstream effectors of the mitogen-activated protein kinase-signaling cascade, leading to melanoma tumor development by an as yet unknown mechanism. In this study, we have identified the role of (V599E)B-Raf in melanoma tumor development by characterizing the mechanism by which this mutant protein promotes melanoma tumorigenesis. Small interfering RNA targeted against B-Raf or a Raf kinase inhibitor (BAY 43-9006) was used to reduce expression and/or activity of (V599E)B-Raf in melanoma tumors. This inhibition led to reduced activity of the mitogen-activated protein kinase-signaling cascade and inhibited tumor development in animals. Targeted reduction of mutant (V599E)B-Raf expression (activity) in melanoma cells before tumor formation inhibited tumorigenesis by reducing the growth potential of melanoma cells. In contrast, reduction of mutant (V599E)B-Raf activity in preexisting tumors prevented further vascular development mediated through decreased vascular endothelial growth factor secretion, subsequently increasing apoptosis in tumors. These effects in combination with reduced proliferative capacity halted growth, but did not shrink the size of preexisting melanoma tumors. Thus, these studies identify the mechanistic underpinnings by which mutant (V599E)B-RAF promotes melanoma development and show the effectiveness of targeting this protein to inhibit melanoma tumor growth.

[1]  Christopher J. Miller,et al.  Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. , 2004, The Journal of investigative dermatology.

[2]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[3]  K. Plate,et al.  Inhibition of solid tumor growth by gene transfer of VEGF receptor‐1 mutants , 2004, International journal of cancer.

[4]  K. Taira,et al.  Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference , 2004, Oncogene.

[5]  M. Gore,et al.  BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Kazuhiro Takahashi,et al.  BRAF point mutations in primary melanoma show different prevalences by subtype. , 2004, The Journal of investigative dermatology.

[7]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[8]  E. Voest,et al.  Stimulation of angiogenesis by Ras proteins. , 2004, Biochimica et biophysica acta.

[9]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[10]  G. Bollag,et al.  Raf pathway inhibitors in oncology. , 2003, Current opinion in investigational drugs.

[11]  M. Flaig,et al.  Mutations of the BRAF gene in benign and malignant melanocytic lesions. , 2003, The Journal of investigative dermatology.

[12]  I. Wistuba,et al.  BRAF Mutation: A Frequent Event in Benign, Atypical, and Malignant Melanocytic Lesions of the Skin , 2003, The American Journal of dermatopathology.

[13]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[14]  C. Garbe,et al.  Exclusion of BRAFV599E as a melanoma susceptibility mutation , 2003, International journal of cancer.

[15]  Meenhard Herlyn,et al.  BRAF as a potential therapeutic target in melanoma and other malignancies. , 2003, Cancer cell.

[16]  D. Polsky,et al.  Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. , 2003, Cancer research.

[17]  Z. Ronai,et al.  ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis , 2003, Oncogene.

[18]  L. Desjardins,et al.  BRAF as a melanoma susceptibility candidate gene? , 2003, Cancer research.

[19]  C. Pritchard,et al.  Raf proteins and cancer: B-Raf is identified as a mutational target. , 2003, Biochimica et biophysica acta.

[20]  G. Robertson,et al.  Loss of PTEN promotes tumor development in malignant melanoma. , 2003, Cancer research.

[21]  S. Lowe,et al.  Apoptosis and melanoma chemoresistance , 2003, Oncogene.

[22]  Kun-Liang Guan,et al.  Mechanisms of regulating the Raf kinase family. , 2003, Cellular signalling.

[23]  K. Smalley,et al.  A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? , 2003, International journal of cancer.

[24]  R. MacKie,et al.  Absence of exon 15 BRAF germline mutations in familial melanoma , 2003, Human mutation.

[25]  J. McCubrey,et al.  Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). , 2003, International journal of oncology.

[26]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[27]  R. Jain.  Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. , 2002, Seminars in oncology.

[28]  Richard Wooster,et al.  BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.

[29]  J. McCormack,et al.  Analytical and pharmacokinetic studies with 5-chloro-2'-deoxycytidine. , 2002, Biochemical pharmacology.

[30]  J. Schellens,et al.  Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. , 2002, Cancer research.

[31]  B. Riedl,et al.  Design and discovery of small molecules targeting raf-1 kinase. , 2002, Current pharmaceutical design.

[32]  B. Riedl,et al.  A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer , 2002 .

[33]  Leland J. Gershell,et al.  Selective anticancer drugs , 2002, Nature Reviews Cancer.

[34]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[35]  T. Tsuruo,et al.  P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel , 2002, Cancer Chemotherapy and Pharmacology.

[36]  G. Bollag,et al.  Discovery of a novel Raf kinase inhibitor. , 2001, Endocrine-related cancer.

[37]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[38]  F. Cognetti,et al.  Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. , 2000, Journal of experimental & clinical cancer research : CR.

[39]  P. Hersey,et al.  The chemoresistance of human malignant melanoma: an update. , 1999, Melanoma research.

[40]  W. Cavenee,et al.  In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  U. Rapp,et al.  Endothelial apoptosis in Braf-deficient mice , 1997, Nature Genetics.

[42]  J. Beijnen,et al.  Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.